These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11364944)

  • 1. ICAAC and Hamburg: Part 2. The dry salvages or, what to do with two protease inhibitors.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Dec; 3(12):39-54. PubMed ID: 11364944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitors: resistance, resistance, resistance.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICAAC and Hamburg: Part 1. Schmuddelwetter or, rating protease inhibitors on the pass/fail system.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Dec; 3(12):29-37. PubMed ID: 11364943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antiretroviral drugs part I: PIs.
    Murphy RL
    AIDS Clin Care; 1999 May; 11(5):35-7. PubMed ID: 11367101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of drug cocktail combinations for their immunological value in preventing/remitting opportunistic infections.
    Konlee M
    Posit Health News; 1998; (No 16):2-4. PubMed ID: 11365016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More clinical data on protease inhibitors.
    Smart T
    GMHC Treat Issues; 1995 Oct; 9(10):4-7. PubMed ID: 11362917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitors: no knockout blow, but could be the best punch yet.
    AIDS Alert; 1996 Apr; 11(4):37-9. PubMed ID: 11363400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease developers skirmish over possible pitfalls.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Mar; 1(2):13-6. PubMed ID: 11362309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage therapy: still more intuition than data.
    Gilden D
    GMHC Treat Issues; 1999 Jan; 13(1):6-12. PubMed ID: 11366112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After the drugs: what's next?
    Schouten JT
    Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICAAC 1995: new perspectives on treatment.
    James JS
    AIDS Treat News; 1995 Sep; (no 231):1-2. PubMed ID: 11362866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigms, platitudes, opportunists.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):16-24, 26-9 contd. PubMed ID: 11362971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.